Privo Technologies
Peabody
About Privo Technologies
At Privo Technologies, they are developing an entirely new class of targeted treatments such as chemotherapy drugs, radiation sensitizers and radiation protectors and mitigators. Their proprietary nano-engineered platform is based on innovations in nanotechnology and material science discovered at MIT's Langer laboratory. Privo's platform is designed to create robust treatments for a wide range of indications while reducing or limiting the treatments harmful side effects. They deliver drugs via the mucosa with the initial focus on oral cavity mucosa. They are excited about building a pipeline of treatments with a range of product candidates in oncology, infectious diseases, and radiation. Their initial product candidate is a treatment for the critically underserved worldwide market of oral cancer. They are developing their novel targeted treatments for worldwide markets at their facilities in the greater Boston area.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $5.7M
- Last round: Grant (Feb 2022)
- Website: privotechnologies.com
- Phone: 978-587-2322
Industries & Categories
Biotechnology, Health Care, Medical, Nanotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/privo-technologies-33210 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.